Diagnosis

Endocarditis

Infection of the inner lining of the heart, which may include the heart valves, the mural endocardium, or a septal defect.

Also known as: Infective endocarditis

Etiology

Cause [3y8]

Pathophysiology [zq9][nq3]

  1. Prodromal endocardial injury (catheter/electrode/surgery/IV drugs) --> Turbulence or trauma to the endothelial surface (fibrin-platelet vegetation)

  2. Medical procedure (oral surgery, endoscopy) --> Bacteremia delivers the organisms

  3. Adherence of the organisms

  4. Eventual invasion of the valvular leaflets --> vegetations:

    • Septic emboli

    • Circulating immune complexes (glomerulonephritis and vasculitis)

Risk factors [zq9][nq3]

Complications [zq9][nq3]

Epidemiology

Incidence per 100.000 [tow][91h][3y8][qn7][w4d][s31]

Epidemiology chart for Incidence

Symptoms & findings

Symptoms

Anorexia, Aphasia, Arrhythmia, Arthralgia, Arthritis, Ataxia, Blindness, Chills, Coma, Confusion, Cough, Delirium, Dysphagia, Dyspnea, Fatigue, Fever, Headache, Heart murmur, Hematuria, Malaise, Myalgia, Nail clubbing, Neck stiffness, Night sweats, Pallor, Paralysis, Paresis, Paresthesia, Splenomegaly, Vomiting

Clinical findings

Friction rub

Anamneses

Drugs, Surgery

Localized findings

Pain
Radiates
CaputThoraxRUQ (Right Upper Quadrant)RLQ (Right Lower Quadrant)Back
Onset
Acute (minutes)Subacute (hours)Gradual (days)
Pattern
Constant
Severity
Mild (1-3)Moderate (4-7)
Rash
Radiates
CaputCollumThoraxAbdomenGenitalArmBackLower body
Lesion type
MaculeNodulePetechiaPurpura

Approach

Dukes clinical criteria for diagnosis

Major Criteria

  1. Blood culture positive for typical microorganisms consistent with endocarditis from 2 separate blood cultures: Viridans streptococci, Streptococcus bovis, HACEK group (Haemophilus spp., Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella spp., and Kingella kingae), Staphylococcus aureus; or community-acquired enterococci

  2.  Transesophageal echocardiogram:

    • Oscillating intracardiac mass on valve

    • Abscess

    • New partial dehiscence of prosthetic valve

  3. New valvular regurgitation (worsening of pre-existing murmur not sufficient)

Minor Criteria

  1. Predisposing heart condition, or injection drug use

  2. Fever, temperature >38° C

  3. Vascular phenomena: major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway lesions

  4. Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth’s spots, and rheumatoid factor

  5. Microbiological evidence: positive blood culture but does not meet a major criterion as noted above or serological evidence of active infection with organism consistent with endocarditis

Treatment

American College of Cardiology - Practice Guidelines: [zgu]

  1. Antibiotic therapy with guidance from blood culture sensitivity [nq3]

    • Native valve: Ceftriaxone 2 g/day + Gentamicin 3 mg/kg/day for 2-4 weeks

    • Prosthetic: Penicillin G 24 million IU/day or Ceftriaxone +/- Gentamicin for 6 weeks

    • MRSA: Vancomycin 15mg/kg/12hr or Daptomycin 8 mg/kg/day for 6-weeks

  2. If embolism --> consider to temporarily discontinue anticoagulation

  3. If pacer/ICD present --> remove hardware

  4. Surgery if:

    • Valve dysfunction causing heart failure

    • Resistant organism (S.aureus, fungi)

    • Heart block or abscess

    • Persistent infection (>7 days after onset of antibiotics)

    • Relapsing prosthetic valve endocarditis

    • Persistent vegetations despite appropriate antibiotic therapy

    • Mobile vegetations greater than 10 mm in length

Differential diagnoses

Abdominal abscess, Antiphospholipid syndrome, Aortic dissection, Discitis, Heart failure, Intracerebral hemorrhage, Lyme disease, Meningitis, Myocardial infarction, Myocarditis, Myxoma, Pericarditis, Pleural empyema, Pneumonia, Polymyalgia rheumatica, Pulmonary embolism, Reactive arthritis, Rheumatoid arthritis, Stroke, Systemic lupus erythematosus, Temporal arteritis, Tricuspid regurgitation, Vasculitis


References

[1] Hammond-Haley M, Hartley A, Al-Khayatt BM, Delago AJ, Ghajar A, Ojha U, Marshall DC, Salciccioli JD, Prendergast BD, Shalhoub J. Trends in the incidence and mortality of infective endocarditis in high-income countries between 1990 and 2019. Int J Cardiol. 2023 Jan 15;371:441-451.

[2] Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, D'Aiello I, Picchi A, De Sensi F, Habib G. Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. Cardiovasc Diagn Ther. 2017 Feb;7(1):27-35.

[3] Yallowitz AW, Decker LC. Infectious Endocarditis. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557641/

[4] http://emedicine.medscape.com/article/216650 (2014-01-18); [Medscape]

[5] Chen H, Zhan Y, Zhang K, Gao Y, Chen L, Zhan J, Chen Z, Zeng Z. The Global, Regional, and National Burden and Trends of Infective Endocarditis From 1990 to 2019: Results From the Global Burden of Disease Study 2019. Front Med (Lausanne). 2022 Mar 9;9:774224.

[6] Anuforo A, Aneni E, Akintoye E, Anikpezie N, Patel SD, Soipe A, Olojakpoke E, Burke D, Latorre JG, Khandelwal P, Chaturvedi S, Ovbiagele B, Otite FO. Trends in Age, Sex, and Racial Differences in the Incidence of Infective Endocarditis in Florida and New York. Circulation. 2024 Apr 23;149(17):1391-1393.

[7] Ahtela E, Oksi J, Porela P, Ekström T, Rautava P, Kytö V. Trends in occurrence and 30-day mortality of infective endocarditis in adults: population-based registry study in Finland. BMJ Open. 2019 Apr 20;9(4):e026811.

[8] Sousa, C., Nogueira, P. & Pinto, F.J. Insight into the epidemiology of infective endocarditis in Portugal: a contemporary nationwide study from 2010 to 2018. BMC Cardiovasc Disord 21, 138 (2021).

[9] Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O'Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD; ACC/AHA Task Force Members. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 10;129(23):2440-92.

Scroll to top